Background: The WHO and UNICEF recommend therapeutic zinc supplementation (TZS) for the treatment of diarrhea. In zinc-deficient populations, preventive zinc supplementation might provide greater benefits for reducing diarrhea and malaria incidence and increasing growth and plasma zinc (pZn) concentration. If effective, intermittent preventive zinc supplementation (IPZS) would cost less than daily preventive zinc supplementation (DPZS).
Introduction
Zinc deficiency is common in children in low-income countries, and it increases the risk and severity of common infections, such as diarrhea and pneumonia (1) . Several pooled and meta-analyses found that daily preventive zinc supplementation (DPZS) 9 increased plasma zinc (pZn) concentration (2) (3) (4) , reduced the incidence of diarrhea (3) (4) (5) (6) (7) and acute lower respiratory infection (3, (5) (6) (7) , and increased childrenÕs growth (2) (3) (4) 8) , although there was substantial heterogeneity of results. Some investigators have also reported a reduction in severe malaria (9) (10) (11) , but the evidence is less consistent (4, 7, 12, 13) .
Studies of zinc supplementation in the treatment of diarrhea found a reduced duration of the illness in children >6 mo of age (14) (15) (16) , and the WHO and UNICEF recommend providing 20 mg Zn/d for 10-14 d, along with oral rehydration salts (ORS) and continued feeding, for the treatment of diarrhea (17) . This treatment regimen has been deployed in many countries as part of their national diarrheal disease control programs. However, this strategy seems suboptimal for the prevention of zinc deficiency, because 1) children have access to supplemental zinc only after they become ill with diarrhea, and 2) they receive supplemental zinc only if their caregivers actively seek treatment for diarrhea, which may be problematic in settings such as West Africa, where diarrhea is frequently underrecognized and undertreated (18, 19) .
An innovative strategy to overcome these limitations would be to provide intermittent preventive zinc supplementation (IPZS), whereby children would receive daily zinc supplements for short periods of time at regular intervals, regardless of their diarrhea status. Although pZn concentration decreases shortly after discontinuation of zinc supplementation (20) (21) (22) , some studies of short-term (10-14 d) therapeutic zinc supplementation (TZS) for diarrhea suggest that supplemental zinc may reduce the incidence of new episodes of diarrhea (23) (24) (25) and increase growth during the 2-3 mo after treatment, although the evidence is inconsistent (20, 22, 26) . Because of the reduced number of supplements required for IPZS compared with DPZS, the former strategy has the potential to be the most cost-effective form of preventive zinc supplementation (27) , but studies are needed to confirm its efficacy and effectiveness (28) .
The objective of the present study was to identify the most efficacious strategy that could be implemented both to prevent the effects of zinc deficiency on childrenÕs morbidity and growth and to treat diarrhea in a population with an elevated risk of zinc deficiency.
Methods
Research design and study site. This study (NCT00944359) was designed as a cluster-randomized, partially masked, community-based, mixed efficacy/effectiveness trial of different zinc supplementation strategies and was carried out in the Orodara Health District in southwestern Burkina Faso from December 2010 to February 2012. Previous studies indicated that zinc deficiency may be common in the study population (29) (30) (31) .
Ethics. The trial protocol was approved by the Ethical Committee of the Centre Muraz in Burkina Faso and the Institutional Review Board of University of California, Davis. Informed consent was documented by the signature or fingerprint of one of the caregivers, in the presence of an impartial witness when the caregiver was not literate.
Inclusion criteria, random assignment, and baseline assessments.
Potentially eligible children were identified during an initial populationbased survey (19) . Children were eligible for the study if they were 6-27 mo of age, resided within the study communities, and were not supplemented with zinc. Exclusion criteria were the following: weight-for-height z score <70% of the National Center for Health Statistics/WHO growth reference median (32) or presence of bipedal edema, hemoglobin <50 g/L, acute illnesses requiring inpatient treatment, or known congenital abnormalities or chronic diseases that may affect growth or risk of infection.
For the purpose of randomization, we divided the study area into 36 geographically defined clusters stratified by selected characteristics (urban/rural and distance from main hospitals). Then, a statistician at the University of California, Davis, randomly assigned clusters within a stratum to 1 of 3 schedules for initiation of the supplementation (Figure 1) . The purpose of stratification was to help ensure even distribution of different types of communities during each of the three 16-wk rounds of the study. The 3 possible intervention schedules were as follows: 1) immediate supplementation (beginning in round 1), 2) delayed supplementation (beginning in round 2 or 3), or 3) nonintervention. Communities allocated to delayed supplementation further were randomly assigned to start enrollment and morbidity surveillance (but not supplementation) in round 1, 2, or 3 for a period of 16 wk before supplementation was started. This randomization was performed at the cluster level to facilitate logistics and limit possible spillover of supplementation to children assigned to the delayed supplementation or nonintervention groups. During each round, one of the delayed intervention groups served as a nonsupplemented group for comparison of morbidity data with the groups currently assigned to receive supplementation.
Once supplementation was scheduled to start, study nurses randomly assigned eligible children to 1 of the 3 supplementation regimens at the level of concession (extended family compound) with the use of a block randomization scheme with a block length of 6. The 3 supplementation regimens were IPZS, DPZS, and TZS for episodes of diarrhea. Thus, the trial had a total of 5 arms, as illustrated in Figure 1 and Table 1 : IPZS, DPZS, TZS, morbidity surveillance control (MSC) and nonintervention control (NIC).
At enrollment, we measured the height and weight of all the children and their mothers, and we assessed childrenÕs hemoglobin concentration, presence of malaria by rapid diagnostic test (RDT) (Malaria Ag P.f/Pan; SD Standard Diagnostics), and dietary diversity as per standard recommendations (33) . Anthropometric assessments were repeated after 16, 32, and 48 wk. At the 16-wk and 32-wk follow-up visits, children >27 mo of age exited the study and newly eligible children >6 mo of age were enrolled. Each child therefore could contribute to 1, 2, or 3 of the 16-wk periods of observation.
Children who were ill at the time of enrollment received free medical treatment for selected illnesses or were referred to the nearest health center. The study team provided ORS for diarrhea, acetaminophen for fever, and artemether-lumefantrine and acetaminophen when the malaria RDT was positive. Children with hemoglobin <80 g/L received anthelminthic treatment (mebendazole, 200 mg/d for 3 d) and iron supplements (2-6 mg Fe/kg body weight for 30 d).
Socioeconomic characteristics of the village, concession, household, and mother were assessed during the initial population-based survey in the study area (19) . Improved water source and improved toilets were defined according to standard guidelines (34) .
In the immediate supplementation communities and the NIC group, all children 6-18 mo old without diarrhea or fever in communities chosen on the basis of field logistics were assigned to the biochemical subgroup (n = 703 children) for a venous blood draw at enrollment and after 48 wk.
Once enrolled, children were excluded from the trial if they had not consumed supplements or had not provided morbidity surveillance information for >14 consecutive days. Their information was included in the analyses until the time of dropout.
Delivery of supplements. Ten supplement tablets were provided at enrollment and again every 16 wk at the time of the follow-up anthropometric assessments. These tablets contained 7 mg Zn in the DPZS group, 10 mg Zn in the IPZS group, and no zinc in the TZS group. During the subsequent weekly home visits, the field worker delivered a new set of 7 tablets for daily administration. These tablets contained 7 mg Zn in the DPZS group, and no zinc in the IPZS and TZS groups. In cases of diarrhea, caregivers were advised to visit a community health worker (CHW) appointed by the project, who provided ORS and 10 therapeutic supplement tablets. Theses tablets contained no zinc in the DPZS and IPZS groups and 20 mg Zn in the TZS group. At the time of enrollment, caregivers were instructed on how to dissolve the dispersible table and to give the tablets $30 min before or after serving food. The field worker recorded reported consumption of all supplements and collected empty packages and any remaining daily supplements to assess the disappearance rate.
All supplements were manufactured by Nutriset. Active supplements contained zinc sulfate, and placebo tablets were identical in appearance Comparison of 3 zinc supplementation strategies 2059 and flavor. Adequate zinc content of supplements (0 mg, 7 mg, 10 mg, or 20 mg Zn) was confirmed by an independent laboratory: analyzed zinc content [mean (range)] was 0.0 (0.0-0.0) mg, 7.1 (6.6-7.4) mg, 10.0 (9.5-10.5) mg and 19.9 (19.0-21.0) mg. Supplements were color-coded according to the intervention group, and the investigators, study staff, and participants remained blinded during field implementation and data analysis. Children did not receive placebo tablets if they were assigned to the NIC group or during the initial period of morbidity surveillance in the delayed intervention clusters (MSC group).
Morbidity surveillance and treatment. A dedicated field worker visited the homes of all participants weekly, except for those in the NIC group. The field worker recorded reported morbidity symptoms for each day of the previous week, including number and consistency of stools, and presence of vomiting, fever, and other illnesses. The field worker also encouraged the caregiver to visit the communityÕs study-appointed CHW for treatment of uncomplicated diarrhea, fever, or malaria, or the health center in case of specific danger signs, respiratory distress, complications of diarrhea or malaria, or other illnesses.
In each intervention community, $1 CHW was trained to follow a simple algorithm to identify and treat uncomplicated diarrhea, fever, and malaria according to the national guidelines, and to refer children with other illnesses or illness complications to the health center. In the case of diarrhea, the CHW provided children in the intervention communities with ORS and 10 d of therapeutic supplements (zinc or placebo, depending on group assignment). Children in the MSC received ORS only. In the case of reported fever, the field worker or the CHW measured body temperature and performed an RDT. Children with confirmed fever received acetaminophen, and children with confirmed malaria received acetaminophen and artemether-lumefantrine.
Diarrhea was defined as the presence of >3 loose or liquid stools/24 h. Reported fever was defined as any fever reported by the caregiver. Confirmed fever was defined as axillary temperature >38.0°C. An episode of diarrhea or fever was composed of all consecutive days of reported symptoms, with a maximum of one symptom-free day within any episode. An episode of diarrhea was defined as severe when accompanied by $1 d with $6 liquid or semiliquid stools, dehydration, hospitalization, and/or death. An episode of malaria was defined as any episode of reported or confirmed fever beginning on a day at risk of a new malaria episode and associated with a positive RDT or a positive blood smear within 48 h; or beginning any day if the parasite involved was different from the previous malaria episode. A day at risk of a new malaria episode was defined as any day a child had not received antimalarial treatment for a confirmed malaria episode within the previous 21 d. The incidence of all these illnesses and the prevalence of diarrhea were calculated separately for each of the 16-wk periods of morbidity surveillance. Each child could therefore contribute to 1, 2, or 3 child-periods of observation.
Anthropometric measurements. Anthropometric measurements were performed in duplicate at enrollment and every 16 wk. The recumbent length of children was measured to the nearest 0.1 cm (SECA 417). Unclothed children were weighed on a baby scale (SECA 383) to a precision of 50 g or, when too agitated, in the caregiverÕs arms on an adult scale to a precision of 100 g (SECA 874 and SECA 876). Anthropometric equipment were calibrated daily, and anthropometric teams were standardized monthly; the technical errors of measurement for length (mean, 0.43 cm; range: 0.27-0.67 cm) and weight (mean, 45 g; range: 30-105 g) were considered to be acceptable (35) .
Length-for-age z score (LAZ), weight-for-length z score (WLZ), and weight-for-age z score (WAZ) were calculated according to the WHO (37) . Stunting, wasting, and underweight were defined as LAZ, WLZ, and WAZ <22, respectively.
Specimen collection and laboratory analysis of biomarkers of nutritional status. Hemoglobin concentration was measured with a HemoCue 201+ photometer with the use of capillary blood samples obtained from all children at baseline and venous blood samples from children in the biochemical subgroup after 48 wk. Venous blood samples were collected in trace element-free lithium heparin tubes while following the guidelines by the International Zinc Nutrition Consultative Group (38) . When a child was acutely ill with diarrhea or fever on the day of the final blood drawing, the blood collection was postponed until the symptoms resolved, and supplementation was continued. Samples were placed in a cold box (0-8°C) immediately after collection and centrifuged within 8 h. Plasma samples were stored at 220°C and shipped on dry ice to collaborating laboratories for analysis. pZn concentration was measured by inductively coupled plasma optical emission spectrophotometry (VWR International) at the ChildrenÕs Hospital of Oakland Research Institute in California (29, 39) . Soluble transferrin receptor (sTfR), plasma ferritin (pF), retinol-binding protein (RBP), C-reactive protein (CRP), and a-1 acid glycoprotein (AGP) concentrations were measured in plasma by ELISA at the VitMin laboratory (40) .
sTfR, pF, RBP, and pZn were adjusted categorically (CRP $10 mg/L and/or AGP $1 g/L) for inflammation (41) . Deficiency for each indicator was defined as follows: hemoglobin <110 g/L for anemia; sTfR >8.3 mg/L or pF <12 mg/L for iron deficiency; RBP <0.83 mmol/L for vitamin A deficiency; and pZn <65 mg/dL for zinc deficiency.
Sample size estimation. The sample size estimate was based on the number of children needed to detect a difference in mean annual diarrhea incidence between any 2 intervention groups, with an effect size of 0.20 (significance = 0.05, power = 0.80), which is the magnitude that is deemed to be of public health importance and consistent with previous trials (3, 5) . The sample size for growth over 48 wk was based on a 4-group comparison and an effect size of 0.25, as previously observed (2) . With the use of the assumption of 1.5 as an estimated design effect from cluster randomization and an attrition of 15%, a sample size of ;900 subjects was needed per group in the supplemented groups, ;800 in the MSC group, and ;1200 in the NIC group. Including the abovementioned assumptions, an attrition rate of 20%, and an effect size of 0.5, the target sample size for biochemical indicators was 160 children/study group in the immediate supplementation communities and 220 in the NIC group (total sample size = 700).
Data management and data analysis. Data were entered in duplicate in an EpiData database, entry version 3.1. Data management and statistical analyses were performed with the use of the SAS System, version 9.3. Outliers were retained in the analysis unless there was a specific reason to believe the value was false. Participants whose pZn exceeded 5 SDs above the mean at baseline (n = 1) or end line (n = 1) were considered to be contaminated and excluded.
Socioeconomic, anthropometric, and morbidity data at enrollment were compared by study group and by completion status with the use of a chi-square test for categorical variables (SURVEYFREQ procedure) and ANOVA for continuous variables (HPMIXED procedure).
Mixed models were used to take the cluster design into account and, when relevant, repeated observations for the same child. The units of analysis for comparisons between intervention groups were the 16-wk child-periods of observation for morbidity and growth. Individual children who were enrolled in the study for 48 wk served as the unit of analysis for the comparisons of biochemistry and growth outcomes over 48 wk. For continuous variables, the effect of the study group was compared by ANCOVA (MIXED procedure), after transformation when necessary. Incidence and prevalence data were compared across study groups with the use of logistic regression (GENMOD procedure for binary distributions) with an event/trial specification of the response variable (42) . For incidence, we modeled the appearance of a new episode of a given illness (event), taking into account the number of observation days at risk (trial). For prevalence, we used the same model with the use of presence of a given illness as the event. We performed multiple comparisons of means with the use of the Tukey-Kramer adjustment. All multivariable models controlled for the outcome baseline value, any group-wise difference in baseline characteristics, and other potential confounding factors (including duration of supplementation, timing of enrollment, age, and sex) if they remained associated with the outcome at a level of significance < 0.05. Values in the tables are presented as adjusted means 6 SEs, unless stated differently.
Results
Study profile and baseline characteristics. A total of 7907 children in 36 clusters were screened for eligibility. Of these, 7641 children were enrolled, and they contributed 11,456 16-wk child-periods of observation and 10,029 follow-up anthropometric assessments over the whole study (Figure 2) . During the course of the study, 1743 children received IPZS (3125 childperiods); 1743 received DPZS (3122 child-periods); and 1766 received TZS (3101 child periods) for durations that ranged from 1 to 50 wk (mean 6 SD: 17.7 6 12.7). A total of 2339 children were included in the MSC group (2339 child-periods), and 1216 children were included in the NIC group.
The proportion of participants who completed the study (87%) did not differ between study groups. There were no differences in baseline biochemistry, reported morbidity, or anthropometrics between children who completed the study and those who dropped out, except that noncompleters were slightly younger at enrollment (45.4% were 6-11 mo old and 28.6% were 12-17 mo old at enrollment compared with 43.9% and 26.5%, respectively, in completers, P < 0.001), and consequently less likely to be stunted (26.0% compared with 29.4%, P = 0.002). The difference in stunting prevalence was no longer significant after controlling for age.
The childrenÕs age (mean 6 SD) was 14 6 6 mo at enrollment, and 28.6% were stunted and 14.3% were wasted. Most children (88.5%) were anemic, and 60.4% had a positive malaria RDT. Breastfeeding was common in children, but adequate dietary diversity was infrequent (Supplemental Table 1 ). Maternal age (mean 6 SD) was 26 6 7 y, and 76% of mothers had no formal education. The study area was characterized by large households, the majority of which did not have access to improved water or sanitation facilities.
Compliance with treatment. Reported adherence to the preventive supplements was very high (98-100%), but lower for therapeutic supplementation (47%; Table 2 ). The guardians sought treatment from the CHW during just 61.8% of reported diarrhea episodes, although among those who visited the CHW, reported adherence was fairly high at 72% of scheduled doses. Reported adherence to either form of supplement did not differ by supplementation group. Based on reported adherence, the additional daily zinc intake from the supplements (mean 6 SD) was 0.9 6 0.4 mg/d in the IPZS, 6.8 6 0.3 mg/d in the DPZS, and 0.5 6 0.9 mg/d in the TZS groups.
Biochemical indicators of nutritional status. Systemic inflammation was very common at baseline, with 23.3% of children having elevated CRP concentrations and 53.5% having elevated AGP. After adjustment for inflammation, 90.1% of children had high sTfR, 50.5% had low pF, 48.9% had low RBP, and 43.5% had low pZn concentrations.
After 48 wk of supplementation, pZn increased significantly more in the DPZS group than in the TZS and NIC groups, but there was no significant difference in change from baseline compared with the IPZS group ( Table 3 ). The provision of the different types of zinc supplements did not affect the change in hemoglobin, sTfR, pF, and RBP concentrations (P > 0.5).
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Morbidity. During the 11,456 child-periods of observation, caregivers and/or CHWs reported 6356 episodes of diarrhea, including 1238 episodes of severe diarrhea, and 14,174 episodes of fever, of which 6095 cases were confirmed and 3486 were associated with a positive malaria RDT or blood smear. The reported incidences of diarrhea, severe diarrhea, fever, and malaria were low, and there was no significant difference between the 3 supplementation groups for any of these illnesses ( Table 4 ). However, all 3 groups had significantly fewer episodes of reported diarrhea and reported fever than the simultaneously observed MSC group. Reported severe diarrhea incidence followed the same trend, although these results were not statistically significant (P = 0.06). In contrast, there was no significant difference between the supplemented groups and the MSC group in the incidence of confirmed fever or confirmed malaria, or in the prevalence of diarrhea.
Growth. The prevalence of stunting, wasting, and underweight was high at baseline and did not differ between the groups after controlling for age. There was no significant difference in growth between the 3 zinc-supplemented groups over the 16-wk periods ( Table 5 ) or over the full 48 wk (Supplemental Table 2 ).
There was also no difference in growth between any of the supplemented groups or between the supplemented groups and the NIC group over 48 wk. However, when all 16-wk childperiods of observation of the 3 rounds were pooled, children in the MSC group gained slightly more length (+1.6-2.1 mm/16 wk) and lost slightly less LAZ (20.07 to 20.08 LAZ/16 wk) than any of the 3 supplemented groups ( Table 5 ). There were no group-wise differences in weight increments during these 16-wk periods, so the change in WLZ was marginally less in the MSC group than in the supplemented groups. The childrenÕs initial nutritional status did not modify the effect of study group on their growth increments.
Discussion
The study results indicate that providing children with either one of the 3 forms of zinc supplementation reduced the incidence of reported diarrhea and fever and marginally reduced the incidence of reported severe diarrhea (P = 0.06) compared with providing no zinc supplements to children who were observed concurrently, and the 3 supplemented groups did not differ from each other. However, there were no differences between any of the 4 groups included in the surveillance with regard to objectively diagnosed malaria incidence (as determined by RDT) or fever (as assessed by measuring body temperature), or with regard to reported diarrhea prevalence. Because of the differences in reported symptoms compared with observed signs of illness, especially for fever, and the differences in diarrhea outcomes depending on their duration or severity, 2 different interpretations of the study results are possible. One possible conclusion is that zinc supplementation reduced the incidence of diarrhea and febrile illnesses, regardless of the cumulative dose and frequency of administration of supplemental zinc. These effects of supplemental zinc on reducing morbidity would be consistent with the results of previous studies of daily or weekly preventive zinc supplementation, which found substantial reductions in the incidence of diarrhea (3-7), but an inconsistent impact on malaria (4, 7) . Likewise, some studies reported reduced diarrhea incidence for a period of time after short-term therapeutic supplementation for diarrhea (23) (24) (25) , although this outcome has not been observed consistently (20, 22) . If each of the supplemented groups did indeed have a reduced incidence of diarrhea and fever, this would imply that supplemental doses as low as 0.5 mg Zn/d could reduce the incidence of these illnesses. One previous dose-response trial in Ecuadorian children found that daily preventive doses as low as 3.0 mg Zn/d reduced diarrhea incidence, but the maximum impact on diarrhea occurred at a dose of 7.0 mg/d (43) . Thus, it is uncertain if the low average doses provided to children in the IPZS and TZS groups in the current study would actually be sufficient to produce this apparent impact.
An alternative interpretation of the study results is that none of the zinc supplementation regimens produced a true reduction in the incidence of diarrhea and fever, and the differences in these reported illness symptoms between the supplemented groups and the MSC group were due to reporting bias. This interpretation would explain the inconsistency between the reported and documented fever. Moreover, the lack of zinc responsiveness in the present study population would be consistent with results from a recently reported intervention trial in a neighboring health district of Burkina Faso, which found that children who received DPZS as dispersible tablets (5 mg Zn/d) or small-quantity lipid-based nutrient supplements containing 0, 5, or 10 mg Zn/d had no differences in morbidity from diarrhea, fever, or malaria (44, 45) . Thus, it is possible that zinc supplementation is not effective in this population, despite the seemingly high risk of zinc deficiency, because of other underlying nutritional deficiencies, poor adherence to the supplementation regimens, or other confounding factors. Adherence to preventive supplementation was reportedly high, although previous studies in neighboring communities suggest that some overreporting may occur (46) . Nevertheless, the significant increase in pZn in the DPZS group compared with the TZS and NIC groups indicates some level of compliance with the DPZS. Almost all studies of preventive zinc supplementation, including a study of directly observed supplementation in a neighboring community in Burkina Faso (29) , have found an increase in pZn (3, 4) , although the effect of supplementation is relatively short-lived (21) . Thus, it is not surprising that the IPZS and TZS groups did not differ from the NIC group, because the effects of supplementation would have disappeared by the time of the final blood collection (except perhaps in the small subgroup of children with a very recent episode of treated diarrhea in the TZS group).
The contradiction between reported symptoms and observable signs of illness could be due to expectations of the caregivers or field staff regarding the impact of intervention products and/or reporting fatigue in the supplemented groups. Because of the use of a rolling control group for morbidity surveillance, caregivers, field workers, and CHWs in the MSC group were newer to the study than those in the zinc-supplemented groups during the second and the third rounds of the study, thereby introducing confounding between the MSC group and length of time involved with morbidity reporting. Reporting fatigue would be consistent with the significantly lower reporting of diarrhea episodes in the supplemented groups than in the MSC group. The rate of attrition and characteristics of dropouts was similar across all study groups and was mostly due to travel out of the study area, so the relatively low level of attrition is unlikely to have biased the results.
There were no significant differences between study groups in any of the growth increments assessed over the full 48-wk period of observation. Previous studies of DPZS have found a small, positive impact on linear growth and weight gain (3, 4, 8) , but there is considerable heterogeneity in these results. The factor that explains most of the heterogeneity in previous studies is the simultaneous administration of other nutrients, especially iron (2). However, this would not have been an issue in the current trial, because zinc was provided without other nutrients, except for in the subset of children with moderately severe anemia, who received supplemental iron for just 1 mo at enrollment (5.9% of total child-periods). Thus, the lack of any growth response to zinc, with a trend toward better growth in the NIC group, was unexpected.
Following the same trend, children in the zinc-supplemented groups gained slightly less in length than those in the MSC group during the 16-wk periods of concurrent observation, although this finding was not mirrored by changes in weight. We do not have a good explanation for this observation, because none of the potential confounding factors that were considered explained these results; based on previous studies, there is no reason to suspect that zinc would have an adverse effect on growth. Secondary analyses suggested that these results were observed consistently in the TZS group, regardless of the amount of zinc consumed and even when no zinc was provided (results not shown). Thus, it does not seem that these small differences were due to zinc supplementation per se. It is possible that providing placebo or zinc supplements may have affected caregiversÕ behavior, such as child feeding and care or treatment seeking, and therefore affected their growth (47) . Strengths of the study include the randomized trial design, adequate sample size for detecting outcomes of interest, and high intensity of morbidity data collection, through both weekly in-home visits (active surveillance) and CHW reports on consultations for sick children (passive surveillance). The inverse relation between the accuracy of illness recall and the length of the recall period is well known (48, 49) , but overly intensive surveillance increases the respondent burden for study household participants and adds to the cost of conducting the trial. Thus, by using a 7-d recall period, we attempted to strike a balance between accuracy and burden and cost, which is also in line with recent recommendations for caregiver reporting on diarrhea, cough, and fever in young children (50) . In addition, we provided caregivers with a simple tool to record key symptoms daily, in order to limit recall bias.
Several limitations of the study also must be recognized. As described above, the study was not fully masked, with caregivers and field staff being aware of which children were not receiving zinc supplements (in the case of the MSC group) and which were receiving neither supplements nor illness treatment (in the case of the NIC group). However, once supplementation was initiated, the form of supplementation was fully masked, so all comparisons of zinc-supplemented groups conformed to ideal randomized clinical trial design. Moreover, the use of a rolling MSC group introduced possible confounding, as described above.
In view of the uncertain interpretation of the current study results, and the possible lack of zinc responsiveness in the study population, we are unable to state whether IPZS is efficacious, or whether TZS has any longer-term benefit for growth or infection control beyond the initially treated episode. Thus, additional studies will be needed to reexamine these issues in populations that are known to exhibit functional responses to zinc supplementation. In the meantime, daily or weekly preventive zinc supplementation is advisable in populations that are likely to be zinc deficient, especially where previous trials have detected benefits of supplementation for child growth or morbidity reduction, and TZS should continue to be offered to all children with diarrhea, as per UNICEF and WHO recommendations.
